Nanowear
Nanowear is a New York-based medical technology company that sells SimpleSense, an FDA-cleared AI diagnostic platform using patented cloth-based nanosensors to capture 85+ biomarkers from the skin for continuous cardiometabolic monitoring, serving CROs, pharmaceutical sponsors, cardiologists, and hospital systems.
- Company typePrivate
- Founded2014
- HeadquartersNew York, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Nanowear does
Nanowear Inc. is a New York-based healthcare technology company founded in 2014 that develops the FDA-cleared SimpleSense platform — a closed-loop AI diagnostic system built on proprietary cloth-based nanosensor technology. The platform's non-invasive, gender-neutral undergarment captures 85+ medical-grade biomarkers per millisecond directly from the skin, continuously recording cardiac, respiratory, vascular, and hemodynamic data. This physiological data feeds proprietary machine-learning algorithms trained on terabytes of unique human data, generating scored clinical-grade cardiometabolic assessments that replace up to eight conventional diagnostic tools. The company holds three FDA 510(k) clearances and is pursuing SOC 2 Type II certification alongside HIPAA compliance.
Nanowear serves enterprise healthcare buyers including clinical research organizations (CROs), pharmaceutical sponsors, cardiology practices, and hospital systems. Revenue is generated through subscription-based and managed-service contracts for clinical trial data services, cardiometabolic assessments, and hospital-at-home remote patient monitoring, with the platform used under the direction of licensed medical professionals. Recent strategic partnerships with Dexcom (March 2025) and Satio (April 2025) extend the platform into glucose monitoring and home-based drug delivery, targeting the $55 billion biopharma and $200 billion telehealth markets.
The company operates with a lean 1-10 employee team and remains private and venture-backed, with limited disclosed funding ($1.5 million seed in 2014). Its go-to-market combines direct enterprise sales to healthcare providers with channel partnerships for platform integrations and ecosystem expansion. Multiple industry awards (Frost & Sullivan, ACC, UCSF Digital Health, Philips Wearables Challenge) and CEO leadership roles at AdvaMed Accel provide external validation of its technology and positioning, though specific revenue scale and detailed ownership information remain undisclosed.
Nanowear firmographics
Firmographics- Name
- Nanowear
- Legal name
- Nanowear Inc.
- Website
- https://nanowearinc.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Nanowear is a New York-based medical technology company that sells SimpleSense, an FDA-cleared AI diagnostic platform using patented cloth-based nanosensors to capture 85+ biomarkers from the skin for continuous cardiometabolic monitoring, serving CROs, pharmaceutical sponsors, cardiologists, and hospital systems.
- Ownership category
- akta.pro rank
Nanowear industry classification
Industry- Product category
- Remote Cardiac Monitoring
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI)
- akta.pro secondary industries
- Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB), Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)
Keywords
Where Nanowear is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Nanowear business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others
Revenue model
- Clinical Research Data Services: Nanowear provides CROs and pharmaceutical sponsors with FDA-approved remote monitoring platforms for clinical trials, enabling patients to participate in studies from home, saving significant direct and indirect costs for research organizations.
- Cardiometabolic Assessment Platform: FDA-approved platform that provides cardiometabolic assessments to healthcare providers, digitally recording and transferring clinical grade diagnostics directly to patients' medical teams at the frequency of the prescribing cardiologist's direction.
- Healthcare at Home Monitoring: Remote patient monitoring services enabling medical teams to view live clinical grade data on FDA-approved platform, providing continuous health monitoring from home with data streamed to healthcare providers.
- Dexcom Integration Services: Partnership with Dexcom to integrate glucose data into the wearable device for real-time comprehensive cardiometabolic health assessments for clinical research and patient care.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Enterprise healthcare provider pricing |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Nanowear product offering
Product offeringCore offering
Nanowear develops and sells the FDA-cleared SimpleSense platform, a remote monitoring and AI diagnostic system that combines a non-invasive cloth-based nanosensor undergarment with a cloud-based machine-learning platform and a patient-facing mobile app. The wearable captures 85+ medical-grade biomarkers per millisecond directly from the skin, and the AI platform produces closed-loop cardiometabolic assessments streamed to clinicians under physician direction. The offering is targeted at healthcare providers, cardiology practices, hospital systems, clinical research organizations, and pharmaceutical sponsors for clinical trials and remote patient monitoring.
Product overview
Nanowear is a health technology company offering the SimpleSense platform — a unified FDA-cleared remote monitoring and AI diagnostic system. The platform consists of three integrated components: (1) the SimpleSense non-invasive undergarment (a cloth-based nanotechnology wearable), (2) the SimpleSense Platform (cloud-based software with closed-loop AI diagnostics), and (3) the SimpleSense App (patient-facing mobile interface). The wearable captures 85+ medical-grade biomarkers continuously from the skin, which are transmitted to the cloud platform where ML algorithms generate scored diagnostic data for clinicians. The system replaces up to eight diagnostic tools in a single platform, covering cardiac, respiratory, vascular, and hemodynamic monitoring for applications in clinical research, heart failure, structural cardiology, primary care, sleep apnea, and post-surgical recovery.
Differentiator
Problem solved
Functional benefit
Brands
- SimpleSense: FDA-approved remote monitoring platform with AI diagnostics that captures 85+ medical grade biomarkers from cloth-based nanosensors worn as an undergarment, enabling full cardiometabolic assessment from home
Products and services
- SimpleSense Platform FDA-cleared remote monitoring and AI diagnostic platform that captures 85+ medical-grade biomarkers per millisecond via cloth-based nanotechnology and delivers closed-loop, clinical-grade cardiometabolic assessments to physicians and clinical research teams. Used under physician direction for clinical trials, remote patient monitoring, and hospital-at-home care.
- SimpleSense Non-Invasive Undergarment One-size-fits-all, gender-neutral, non-invasive undergarment with proprietary cloth-based nanosensors that continuously collects heart rate, heart sounds, respiration rate via thoracic impedance, and physical activity/posture for cardiometabolic monitoring at home.
- SimpleSense App Mobile application that allows users to document symptom-related information while wearing Nanowear remote monitoring devices, with data processed into clinical information communicated to the user's designated medical provider.
- Clinical Research Data Services Subscription-based service that provides CROs and pharmaceutical sponsors with FDA-approved remote monitoring for decentralized clinical trials, integrating each patient's metrics into one location, scored against a shared timeline, with no manual inputs or in-person visits.
- Cardiometabolic Assessment Service FDA-approved assessment service that captures the full symphony of a patient's heart, lungs, vascular, and hemodynamic systems continuously and time-synchronized, replacing up to eight diagnostic tools and digitally transferring clinical-grade diagnostics to the prescribing cardiologist's medical team.
Quantifiable outcome
- 85+ medical grade biomarkers captured per millisecond
- +2 more outcomes
Companies that use Nanowear
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
Nanowear technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability4 records
Feature5 records
Nanowear partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- SatiocoreCollaboration to develop advanced home-based diagnostic and therapeutic solutions integrating Nanowear's AI-based biomarker platform with Satio's blood draw and drug delivery patches. Partnership targets the $55 billion biopharma market and $200 billion telehealth segment, aiming to enhance remote healthcare by merging blood biomarkers with physiological data in a single digital platform.
- DexcomcorePartnership to integrate glucose data from the Dexcom G7 system into Nanowear's wearable device, enabling real-time comprehensive cardiometabolic health assessments for clinical research and patient care. Collaboration expands Dexcom's diabetes management offerings and Nanowear's diagnostic capabilities.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Nanowear competitors and assessment
Company assessmentBroad incumbents
- Preventice Solutions (Boston Scientific): Now part of Boston Scientific, Preventice offers BodyGuardian remote cardiac monitors for ambulatory ECG. Competes in the same hospital-and-cardiologist remote monitoring category as Nanowear's SimpleSense, with broader geographic and payer reach.
- Apple: Explicitly cited by Nanowear's market context as a competitor in cardiovascular digital solutions. Apple Watch offers FDA-cleared ECG and irregular rhythm notifications, providing a consumer-grade alternative that competes for downstream physician attention and payer attention.
- BioTelemetry (Philips): Acquired by Philips, BioTelemetry provides ambulatory ECG and remote cardiac monitoring services at population scale. A broad incumbent in the same remote cardiac monitoring category Nanowear targets, with much larger sales coverage.
Emerging players
- Vivify Health: Remote patient monitoring platform focused on chronic-condition management including cardiovascular disease, sold to health systems and payers. Comparable to Nanowear's healthcare-at-home and cardiometabolic monitoring use cases but with a software-first model rather than a proprietary wearable.
- Dexcom: Leader in continuous glucose monitoring (G7) and a 2025 Nanowear integration partner. While not a direct cardiac competitor, Dexcom's data streams feed Nanowear's cardiometabolic platform, making it both an ecosystem ally and an adjacent wearable chronic-disease monitoring player.
- Withings: Consumer health wearables (ScanWatch, Body Cardio) with ECG and SpO2 capture. Partial overlap with Nanowear on the connected vital-signs wearable axis, primarily consumer rather than clinical-grade.
Direct peers
- iRhythm Technologies: Commercial-stage digital healthcare company focused on ambulatory cardiac monitoring (Zio patch), explicitly named as a competitor in the cardiovascular digital solutions market alongside Nanowear. Both companies sell FDA-cleared remote cardiac diagnostic platforms to clinicians, but iRhythm is single-modality while Nanowear positions as multi-biomarker.
- AliveCor: Developer of KardiaMobile, an FDA-cleared single-lead ECG personal/device, and AI-enabled ECG analysis — overlapping with Nanowear's 2-lead ECG capture and AI diagnostic scoring for clinical and remote-monitoring use cases.
- Eko Health: Maker of digital stethoscopes with FDA-cleared AI cardiac and pulmonary disease detection, capturing heart sounds and ECG for clinician decision support — directly comparable to the cardiac, respiratory and AI-diagnostic elements of SimpleSense.
- VitalConnect: Provider of FDA-cleared wearable biosensor patches (Vista) for continuous remote cardiac and respiratory monitoring in hospital and home settings — directly comparable to SimpleSense's hospital-at-home and continuous cardiometabolic positioning.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Nanowear social profiles
Digital presenceNanowear compliance and trust
Trust signalCompliance3 records
Nanowear financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nanowear leadership team
Management profileNumber of profiles
Profiles2 records
Nanowear funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nanowear M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nanowear
What does Nanowear do?
Nanowear develops and sells the FDA-cleared SimpleSense platform, a remote monitoring and AI diagnostic system that combines a non-invasive cloth-based nanosensor undergarment with a cloud-based machine-learning platform and a patient-facing mobile app. The wearable captures 85+ medical-grade biomarkers per millisecond directly from the skin, and the AI platform produces closed-loop cardiometabolic assessments streamed to clinicians under physician direction. The offering is targeted at healthcare providers, cardiology practices, hospital systems, clinical research organizations, and pharmaceutical sponsors for clinical trials and remote patient monitoring.
Is Nanowear a public or private company?
Nanowear is a private company. It is classified as venture growth investor backed and is currently operating.
When was Nanowear founded?
Nanowear was founded in 2014. It employs 1 to 10 people.
Where is Nanowear based?
Nanowear is headquartered in New York, United States, in the North America region.
How does Nanowear make money?
Four revenue lines are on record. Clinical Research Data Services are the primary driver. The others are cardiometabolic Assessment Platform, healthcare at Home Monitoring and dexcom Integration Services.
Who are Nanowear's main competitors?
Broad incumbents on record are Preventice Solutions (Boston Scientific), Apple and BioTelemetry (Philips). Emerging players are Vivify Health, Dexcom and Withings. Direct peers are iRhythm Technologies, AliveCor, Eko Health and VitalConnect.
Does Nanowear have an API?
No public API is recorded for Nanowear.
What industry is Nanowear in?
Nanowear's product category is Remote Cardiac Monitoring. Its primary akta.pro industry code is HLACAPAI, Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration), with a secondary code of HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables). Its NAICS code is 334510 and its SIC code is 3845.